Melanin-concentrating hormone (MCH) is a cyclic nona-
described in fish as a heptadecapeptide (Asp-Thr-Met-Arg-CysMet-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val (1)). Its structure was relatively conserved throughout evolution, although in mammals the sequence of MCH is a nonadecapeptide with differences mainly in the N terminus (Asp-Phe-Asp-MetLeu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-GlnVal (2)). In rodents, there are now several lines of evidence for the involvement of MCH in the central regulation of feeding behavior as reviewed by Tritos and Maratos-Flier (3). The MCH peptide and its receptor are expressed in the hypothalamus, a region involved in energy balance and food intake (4 -7) . In this particular brain area, MCH mRNA is overexpressed and up-regulated during fasting in ob/ob mice as well as in rats (8, 9) . Intra-cerebroventricular injections of MCH promote feeding in mice and rats (9 -12) . Finally, transgenic mice lacking the MCH gene are lean and hypophagic (13) . Interestingly, in peripheral tissues, MCH also stimulates the release of leptin from isolated rat adipocytes (14) .
The lack of suitable binding conditions, mainly due to the hydrophobic and sticky nature of MCH itself or derivatives (15, 16) , was probably a limitation for expression cloning of the receptor. The MCH receptor was nevertheless recently identified by several groups using reverse pharmacology (17) (18) (19) (20) (21) . The MCH function was assigned to the previously described orphan receptor SLC-1 (22, 23) , using inhibition of forskolin-stimulated cAMP production and induction of calcium rise.
Receptor cloning and association of functional tests open the way to the search for pharmacological tools, especially receptor antagonists that are needed to study receptor functions. One of the possible strategies to this goal is the chemical modification of the natural peptide including peptide shortening, amino acid substitution, and conformation restriction with the help of structure-activity relationships and modeling studies toward optimized nonpeptide ligands. Such a strategy has been successful for the design of subtype-specific antagonists of neuropeptide Y receptors (24 -27) .
In the case of MCH, only two sets of data have been published on the pharmacological action and binding affinity of MCH analogues in vitro. A first series of experiments with fish MCH on fish, frog, or other batrachian skin assays were reported (28 -32) , showing that fish MCH could be shortened at both termini without major loss of the biological activity (29, 31) . It was also shown that the MCH ring was essential (32) and that any modification (including amino acid deletion) of this ring was deleterious for biological activity (30) . A second series of data have been published more recently using membranes from mammalian cells that were tested for their capacity to bind the current labeled derivative of MCH, [Phe 13 , Tyr 19 ]MCH (15, 16, (33) (34) (35) (36) . Among other discrepancies, the reported affinities for salmon MCH in the cell lines used (16, 34) were quite different from those reported at the rat or human cloned receptor (17, 21) . Furthermore, the mRNA for the cloned receptor could not be found in some of those cell lines. 2 Thus, these results cannot be attributed to the MCH receptor. More pharmacological data should be gathered on the cloned human receptor. To date, a single report described studies with MCH analogues (particularly Arg 11 -modified ones) on human MCH receptor reported the design of the weak MCH antagonist [D-Arg 11 ]MCH (37) . It also showed, by site-directed mutagenesis, that the residue Asp 123 in the third transmembrane domain of the receptor was critical in binding and receptor activation.
In the present report, an extensive and detailed structureactivity relationships study of MCH, including a panel of 58 peptides, is presented using two different functional assays on HEK293 cells stably expressing the human MCH receptor, the inhibition of the intracellular cAMP production and the stimulation of [ 35 S]GTP␥S binding on membrane preparations. The minimal peptide sequence maintaining the agonistic activity was found to be the dodecapeptide MCH-(6 -17), which includes the cyclic part of MCH. From this minimal structure, several antagonists with weak (micromolar) to relatively high (0.1 M) potency could be designed.
MATERIALS AND METHODS
Peptides-Most of the natural and modified peptides were purchased from NEOSYSTEM SA, Strasbourg, France, using the classical methods of peptide chemistry. They were prepared on solid phase (see Ref. 38 for example) using Fmoc for ␣-protection (39), tert-butyl type groups for side chain protection, and trityl for cysteine. Arginine was used under its protected form, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl arginine (40) . Final deprotection and cleavage from the resin was achieved by treatment with 90% trifluoroacetic acid in the presence of thiol scavengers. Final purification was obtained by preparative reverse phase chromatography using a C18 Delta-Pak, 15 M, 300 Å, in linear gradients of acetonitrile/water (0.1% trifluoroacetic acid). Head-to-tail cyclic compounds, such as compound 23, were synthesized on an orthochloro-chlorotrityl resin, the N ␣ -Fmoc eliminated by the action of piperidine, the linear protected peptide cleaved from the resin with 1% trifluoroacetic acid, and the cyclic peptide obtained by bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBroP) activation (41) at high dilution. Compounds cyclized over a disulfide bridge, such as compounds 18 -22, were obtained via air oxidation under strong agitation for 16 h at room temperature of the unprotected and cleaved linear peptide in dilute solution. Finally, compounds cyclized over an amide bond, such as compound 3, were assembled on a Merrifield resin using groups of the benzyl type for side chain and final N ␣ protection, and groups of the tert-butyl type for protection of the basic and acidic side chains were involved in the cyclization. After removal of the latter groups under mild acidic conditions (50% trifluoroacetic acid in CH 2 Cl 2 ), cyclization was achieved under activation by PyBroP on the resin, and finally, the cyclic peptide was both freed from its protecting groups and cleaved from the resin by treatment with fluohydric acid. The purity of each peptide assessed by analytical reversed phase HPLC varied between 90 and 99%, and the molecular weight was confirmed by electrospray mass spectroscopy. Analytical data are presented in Table I .
Cloning of the Human MCH Receptor (SLC-1)-Human brain poly(A)
ϩ RNA (CLONTECH) was reversed-transcribed with oligo (dT) [12] [13] [14] [15] [16] [17] [18] using reverse Transcriptase Superscript II (Life Technologies, Inc.). First strand cDNA (corresponding to 1 g of total RNA) was subjected to 35 cycles of amplification using the forward primer 5Ј-GAGACCCAAGCTTCTGGATGGACCTGGAAGCCT-3Ј and the reverse primer 5Ј-GATGACGCGGCCGCTCAGGTGCCTTTGCTTTCTG-3Ј (33) . After an initial cycle of denaturation at 94°C for 1 min, polymerase chain reaction was carried out for 35 cycles with the following cycle conditions: 94°C, 1 min; 55°C, 1 min; 72°C, 3 min with a postincubation of 72°C for 7 min. The expected 1064-base pair fragment was isolated and ligated into pcDNA3.1 (Invitrogen). The recombinant plasmid, pcDNA3.1-SLC1, was sequenced on both strands by automated sequencing (Applied Biosystems 377).
Establishment of a HEK293 Cell Line Stably Expressing the Human MCH Receptor-HEK293 cells grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin were seeded at 5.10 6 cells in a T75 cm 2 culture flask. 24 h later, they were transfected with 10 g of the pCDNA3.1-SLC1 plasmid using LipofectAMINE as described by the manufacturer (Life Technologies, Inc.). The day following transfection, cells were trypsinized, resuspended in complete Dulbecco's modified Eagle's medium containing 800 g/ml of active geneticin, and seeded at different dilutions in 96-well plates that were kept for 2-3 weeks in an humidified CO 2 incubator. At the end of this selection period, isolated clones were picked, amplified, and further characterized by cAMP experiments. One positive clone was subcloned in limited dilution before being used for all the cAMP and [
35 S]GTP␥S experiments.
Intracellular cAMP Assay-Intracellular cAMP was determined using the Flash plate technology (SMP004, PerkinElmer Life Sciences). Briefly, forskolin (15 M) and test peptides diluted in 0.1% bovine serum albumin were added into 96-well flash plates, and incubation was started with the addition of cells (35,000 cells per well). After 15 min at 37°C, incubation was stopped by the addition of the revelation mix, and 2 h later, plates were counted on a TopCount (Packard Instrument Co.).
[ 35 
S]GTP␥S Binding on Membrane
Preparations-Cells grown at confluency were harvested in phosphate-buffered saline containing 2 mM EDTA and centrifuged at 1000 ϫ g for 5 min (4°C). The resulting pellet was suspended in 20 mM HEPES (pH 7.5), containing 5 mM EGTA and homogenized using a Kinematica Polytron. The homogenate was then centrifuged (95,000 ϫ g, 30 min, 4°C), and the resulting pellet was suspended in 50 mM HEPES (pH 7.5), 10 mM MgCl 2 , and 2 mM EGTA. Determination of protein content was performed according to the method of Lowry et al. (42) . Aliquots of membrane preparations were stored at Ϫ80°C until use. Membranes and peptides were diluted in binding buffer (50 mM HEPES (pH 7.4), 100 mM NaCl, 3 M GDP, 5 mM MgCl 2 , 0.1% bovine serum albumin, 10 g/ml saponin). Incubation was started by the addition of 0.2 nM [ 35 S]GTP␥S to membranes (25 g/ml) and drugs and further followed for 45 min at room temperature. For experiments with antagonists, membranes were preincubated with both the agonist and the antagonist for 30 min prior the addition of [ 35 S]GTP␥S. Nonspecific binding was defined using cold GTP␥S (10 M). Reaction was stopped by rapid filtration through GF/B filters followed by three successive washes with ice-cold buffer.
Calcium Flux Measurements-Stable HEK293 cells expressing the human MCH receptor were seeded (40,000 cells per well) into 96-well black-walled culture plates coated with poly-D-lysine 24 h before assay. Cells were loaded with a calcium kit assay buffer (Molecular Devices) containing 2.5 mM probenecid and incubated at 37°C for 1 h in 6% CO 2 atmosphere. After 10 s, the antagonist was added. For antagonist studies, tested substances were added 10 min before the addition of MCH. Increases of intracellular Ca 2ϩ in the presence of peptides were monitored using the fluorimetric imaging plate reader detection system (Molecular Devices) at 488 nM for 120 s.
RESULTS
Peptides-A total of 58 MCH analogues (including genuine MCH) was obtained by synthesis on solid phase with a purity of Ն90%. They included compounds cyclized over the side chain of two cysteines (cystine analogues), compounds cyclized over an amide bond between two amino acid side chains, and head-totail cyclic analogues (Table I ). All peptides were used as tools to establish the ligand structure-activity relationships, both as agonists or antagonists, at the human MCH receptor.
Characterization of the HEK293 Cell Line Stably Expressing the Human MCH Receptor-The HEK293 cell line stably expressing the MCH receptor was selected through MCH-induced inhibition of forskolin-stimulated cAMP production. The density of the MCH receptors, as determined in saturation binding Arg-Cys-Met-Ala-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp 13.14 TEAP (2) (compound 40) significantly affected the potency of these peptides to inhibit forskolin-induced intracellular cAMP level ( Fig. 1 and Table II) . Salmon MCH (compound 45) was slightly less potent than human MCH in this assay ( Fig. 1 and Table II) . Replacement of the two cysteines by two serine residues, leading to a linear MCH analogue (compound 44), dramatically decreased the potency ϳ300-fold ( Fig. 1 and Table II) indicating that the cyclic part of MCH plays an essential role for activity. These MCH analogues were full agonists in the cAMP assay.
Shortening the MCH Peptide-To establish the human MCH structure-activity relationships, a number of analogues were designed following the classical rules of peptide modification (review Fauchère (43)). The last 2 and the first 5 amino acids of MCH (compounds 43, 58, 39, 57, 56, and 31) were not essential since deletions of these amino acids only decreased ϳ10-fold the potency to inhibit forskolin-induced intracellular cAMP level, potency being still in the nanomolar range (Table II) . In contrast, the deletion of Arg 6 (compound 52) shifted the potency a further ϳ10-fold in the cAMP assay. The minimal sequence for a strong activity thus required 12 amino acids, from Arg 6 to Trp 17 (compound 31), i.e. the sequence MCH-(6 -17).
Substitutions and Deletions in the Minimal Sequence of MCH-
The influence of modifications of compound 31 was further evaluated. First, analogue 31 was subjected to an Ala scan (Table III) , which detected mandatory side chains in positions 11 (Arg) and 13 (Tyr) and to a lesser extent in position 8 (Met), since the substitution by Ala led to less active (compound 9) or inactive peptides (compounds 24 and 27). In contrast, the residues Leu 9 , Gly 10 , Val 12 , Arg 14 , and Pro 15 could be individually replaced by Ala without abolishing the biological activity (compounds 17, 20, 25, 29, and 30). Furthermore, the presence of the ring was crucial for activity as already shown for the entire human MCH peptide (see compound 44), since the linear analogue of compound 31, compound 38, in which both cysteines were replaced by serine residues, was inactive in the cAMP assay. Other substitutions of the essential amino acid Arg 11 by other basic amino acids His or Lys (compounds 34 and 35) failed to restore potent agonist activity (ϳ1000 nM, Table III ). In contrast, the key amino acid Tyr 13 could be replaced by Phe in compound 31, the resulting compound 28 keeping a similar biological activity. Finally, inversion of the chirality of Tyr 13 (compound 32) or of Arg 14 (compound 33) led to dramatically less active peptides in the cAMP assay (Table  III) . Starting from compound 31, we made several attempts to reduce the number of amino acids in the ring and to change the type of cyclization. Linear peptides, cyclic head-to-tail peptides, and compounds cyclized over an amide bond between two amino acid side chains were found to be inactive, at least in the cAMP assay (Tables IV and V) .
Characterization of the [ 35 S]GTP␥S Binding Assay, a Tool to Discover MCH Partial Agonists and Antagonists-Strikingly,
all the tested peptides that were active in the cAMP assay behaved as full agonists as compared with MCH. Furthermore, attempts to characterize the antagonist properties of all those "inactive" compounds against 1 or 10 nM of MCH failed to give significant results in the cAMP assay (Table III) . This lack of sensitivity was probably due to intracellular signal amplification of adenylyl cyclase activation. Therefore, another functional model corresponding to the first step of receptor activation, [ 35 S]GTP␥S binding to G proteins, was set up on membrane preparations. MCH induced ϳ1.5-fold stimulation of [ 35 
S]GTP␥S binding in membranes from HEK-SLC-1 cells but not from native cells (data not shown).
Since the use of saponin was shown to increase GTP␥S binding at the adenosine A 1 receptor (44), its effect was also evaluated in our assay. Indeed, saponin dose-dependently induced a bell-shaped curve on [ 35 S]GTP␥S binding to membranes expressing the SLC-1 receptor (Fig. 2) . The peak concentration of 10 g/ml (for 15 g of proteins/ml) corresponding to a 5-fold stimulation was further used. The concentrations of NaCl, GDP, and MgCl 2 were also optimized; they were, respectively, 100 nM, 3 M, and 5 mM (data not shown). The use of saponin did not modify the potency of MCH to stimulate [ 35 S]GTP␥S binding (EC 50 ϭ 4.51 Ϯ 0.52 nM versus 6.05 Ϯ 0.87 nM in the presence of saponin, n ϭ 3) (Fig. 3) . Comparing the two functional assays, there was a rightward shift (ϳ20-fold) in the potency of MCH to stimulate [ 35 S]GTP␥S binding as compared with the cAMP assay (Table II) . This was also the case for the other agonists tested (Tables II and III) . However, the data obtained from [ 35 S]GTP␥S binding were nicely correlated with those gathered from the cAMP assay (r ϭ 0.87, p Ͻ 0.0001, n ϭ 19) (Fig. 4) . Furthermore, the [
35 S]GTP␥S binding assay was able to discriminate between partial and full agonists, as for instance for compound 52, which behaved as a partial agonist (half of the maximal effect of MCH) in this assay, and which was able to reverse MCH-induced [ Table II) .
From Partial Agonists to Antagonists-Beside compound 52, other peptides exhibited partial agonist activity in the [ 35 S]GTP␥S binding test, as compared with MCH (100%). Examples are as follows: compounds 9 (51%) and 27 (36%) of the Ala scan series (Table III) and compounds 34 and 35, the latter being extremely weak (Table III) . The linearization of MCH or b MCH efficacy was set to 100%, and unless otherwise stated, all the peptide efficacies were 100%. c Abbreviations are as in Table I . d No significant effect was seen up to 10,000 nM.
of compound 31, via Ser substitutions at the two Cys residues, also led to weakly potent partial agonists with efficacies, respectively, of 64 (compound 44, Table II ) and 41% (compound 38) (Table III) . The "inactive peptides" in the cAMP assay were further tested in the [ 35 S]GTP␥S binding test. They were inactive alone, but when tested versus MCH (10 nM), some of them showed full antagonist properties (Table III and IV) . Indeed, quite surprisingly, substitution of Arg 14 (compound 33) by DArg led to a mild antagonist (Table III) . The single deletion of Gly 10 or of Val 12 both in Tyr 13 and Phe 13 analogues also led to antagonists (compounds 23, 26, and 22, respectively, Fig. 6 and Table IV ). The replacement of the dipeptide Leu 9 -Gly 10 by aminovaleryl, thus keeping the backbone length constant but eliminating the side chain of leucine, resulted in a completely inactive compound (compound 19, Table IV) . Similarly, an attempt to modify the peptide 31 by substituting the Cys 7 by Ala and by replacing the two dipeptide sequences, Leu 9 -Gly 10 and Pro 15 -Cys 16 by two aminohexanoic acids (compound 1, Table  IV ) failed to produce antagonists. Furthermore, mimics of the ring of MCH were generated, keeping the general shape of the compound 31 (length and ring) but replacing the disulfide bridge between Cys 7 and Cys 16 by an amide bond between diaminobutyric acid (Dab 7 ) and glutamic acid (Glu 16 ). This compound 3 was a partial agonist, with a potency in the 500 nM range and an efficacy of 67% (Table V) . All the other cyclization attempts failed (Table V) .
Starting from the information that compound 52 ([desArg]MCH-(6 -17)) was a partial agonist in [ , and Pro 15 could be individually replaced by Ala without abolishing the biological activity in both assays (Table III) , we designed compound 53 in which not less than five residues were substituted by non-natural residues. This compound was a potent antagonist (K B ϭ 148 nM, Fig. 6 and Table VI). A second compound was synthesized in which the disulfide bridge of compound 53 was replaced by an amide bond between Dab and Asp (compound 54) or ␣,␥-diaminobutyric acid and Asp (compound 55). These compounds were also antagonists of good potency (K B ϭ 158 and 180 nM, respectively, Table VI) and should display enhanced stability in biological fluids. Activity of these antagonists was further confirmed by calcium flux measurement. MCH was able to increase Ca 2ϩ in HEK cells stably expressing the MCH receptor (Fig. 7A) . The MCH activation curve was rightward shifted in the presence of compound 53 at 10 and 30 M (Fig. 7A) . Furthermore, this functional test was able to show the partial agonistic nature of compound 52 as compared with MCH-(6 -17) (compound 31) (Fig. 7B) . DISCUSSION Since the discovery that MCH is involved in many physiological functions, especially in relation to food intake (5, 6, 9, 13, 45) and since the MCH receptor has been recently cloned (17) (18) (19) (20) (21) , the search for MCH receptor antagonists has become an important pharmacological task to explore both the physiological role of MCH and the therapeutic relevance of its receptor antagonists. In fact several studies using lower vertebrates bioassays have been performed to delineate the amino acids required to support MCH activity (46) . However, in view of the differences between the two MCH sequences (fish and human), no extrapolation to mammals can be made without being tested experimentally. Similarly, structure-activity relationships studies of the binding of MCH on various cell lines should be taken cautiously since they were not performed with the genuine human MCH receptor as discussed in the Introduction (15, 16, (33) (34) (35) (36) . The purpose of the present work was therefore to find out the structural requirements for human MCH derivatives to behave as agonists or antagonists at the human MCH receptor stably expressed in HEK293 cells by using the cAMP and [
S]GTP␥S binding assays.
Several studies at other receptors have shown that, due to intracellular signal amplification, detection of partial agonist effects might not be seen with the cAMP assay and that the antagonist effect of new compounds might be difficult to detect (47, 48) . Indeed all the analogues tested in the cAMP assay, when active, were full agonists as potent as MCH. Furthermore, when they were tested (Fig. 4) Chambers et al. (17) at the human receptor. MCH could be shortened at both its C and N termini without major loss of activity, leading to the dodecapeptide 31, MCH- (6 -17) . Similarly, in salmon MCH, the amino acid variations outside the MCH ring had a limited impact on the agonistic effect of the modified peptides (31 by His or Lys (compounds 34 and 35) afforded partial agonists of low to extremely low potency and efficacy. The lack of agonistic activity of the compounds in which Arg 11 was replaced by His or Lys strongly suggests that the negative charge of the chain is not key in the residue interaction with the receptor but rather the chemical nature of this side chain (i.e. guanidinium).
Other modifications of MCH-(6 -17) led to the discovery of pure antagonists. Although the substitution of Tyr 13 by its D-counterpart led to the inactive compound 32, the conversion of Arg 14 to its D-counterpart (compound 33) led to an antagonist with a submicromolar K B (0.75 M). A similar substitution was reported for Arg 11 in the full MCH sequence (37) also leading to an antagonist but of much weaker potency (15.8 M in a calcium flux assay). In attempts to shorten the dodecapeptide 31 within the cystine loop, further deletions were tried, and 14 analogues were generated, 3 of which were antagonists with K B in the micromolar range (compounds 23, 26, and 22), whereas the others were inactive. Interestingly, shorter analogues of the ring of fish MCH have been described (using the scale melanophore bioassay) in which agonist activity was dependent on the composition of both the loop and the N terminus (29) . Inhibition of MCH activity was detected for some of these compounds, which were shown in fact to counteract MCH activity through an interaction with the MSH receptor (30) .
Extensive substitutions with non-natural amino acids, in compound 31, led to the most potent antagonists described so far at the MCH receptor, compounds 53, 54, and 55 (K B 0.1-0.2 M). The antagonist potency of compound 53 was further confirmed in a calcium flux assay. It should be noted that the calcium assay may represent a complement to [ 35 S]GTP␥S binding since both partial agonists (compound 52) and antagonists (compound 53) were easily detectable. In two of these analogues, 54 and 55, the cystine bridge was successfully modified into an amide bond without loss of the antagonistic potency. A similar result was observed for compound 3. Conversely replacing the Cys by Ser in MCH (compound 44) or in MCH-(6 -17) (compound 38) induced a great loss of potency, and these compounds then behaved as partial agonists. The importance of cyclization to keep biological activity has also been documented for the fish MCH (32). In summary, the following key compounds 31, 3, and 53-55 have been discovered in the present study. The dodecapeptide MCH-(6 -17) (compound 31) with a conserved ring was shown to be the minimal sequence for full agonistic activity. These findings open also routes for the discovery of new ligands with optimized biophysical characteristics, such as enhanced solubility, reduced hydrophobicity, and proteolytic stability, still retaining high receptor affinity. Furthermore the structural diversity of agonists, partial agonists, and antagonists reported in the present work might be very informative in the study of MCH and MCH receptor interactions. MCH-(6 -17) will be further used as a pharmacophore in future combinatorial approaches for the generation of large numbers of peptide (54 -56) and non-peptide ligands (57) . Potent small size antagonists made of non-natural amino acids and cyclized over an amide bond, may represent useful tools for the design of new radiolabeled ligands of the MCH receptor and for both in vitro and in vivo studies of MCH functions.
